Qualyst, Inc. Our company was founded in 2001 on discoveries from breakthrough research in the School of Pharmacy at the University of North Carolina at Chapel Hill. For many years, our founders have pursued basic research to understand the fundamental principles behind processes of absorption, distribution, metabolism and excretion (ADME) at cellular and molecular levels, and to relate these processes to drug toxicity (ADMET). ADMET challenges have been and continue to be a major cause of compound attrition during the drug development process, resulting in the loss of millions of investment dollars and valuable research time. The company focuses on commercializing novel and proprietary drug transporter products for drug discovery and development customers. It aims to provide better knowledge to researchers regarding drug candidate compounds – saving organizations valuable time and research dollars in the process. Our products enable better quality research and development decisions, including the direction of resources toward those compounds best suited for development, increasing the probability of success. Our in vitro assays play a crucial role in the assessment of the therapeutic potential of drug candidates, as well as identify and address challenges that arise during the development process and which . Depending on specific technology and business needs, our clients may license our proprietary technologies for internal use, purchase our exclusive research products, select us to act as a contract research organization (CRO), or work with one of our licensed partners or distributors. We count multiple top-tier pharmaceutical companies and innovative biotech companies as clients.